المؤلفون: R Minacori, M Apert, S Leproust, R Monnier, RO Casasnovas, P Brice, RH Borse, J Gandhi, A Rai

المصدر: Value in Health. 25:S55

مصطلحات موضوعية: Health Policy, Public Health, Environmental and Occupational Health

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7ee3d3b9d5aa9040bed560fa2a3b0fae
https://doi.org/10.1016/j.jval.2021.11.254

المؤلفون: RO Casasnovas, Paule-Marie Carli, B. Coudert, François Bailly, Marc Maynadié

المصدر: Blood. 80:1097-1097

مصطلحات موضوعية: Immunophenotyping, business.industry, Immunology, Cancer research, Medicine, Cell Biology, Hematology, business, Biochemistry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d5c459a22b3e21de720549b33e9432
https://doi.org/10.1182/blood.v80.4.1097.1097

المؤلفون: Maynadié M, Bailly F, Ro, Casasnovas, Bruno Coudert, Pm, Carli

المصدر: Europe PubMed Central

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2631a0eb97d9beca8f835c1a15f74e3b
http://europepmc.org/abstract/med/1463536

المؤلفون: Sesques P; Hematology Department, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69410, Pierre Bénite, Lyon, France., Kirkwood AA; Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK., Kwon M; Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Rejeski K; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany., Jain MD; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA., Di Blasi R; Hematology Department, Hôpital Saint Louis, Paris, France., Brisou G; Hematology Department, Institut Paoli Calmettes, Marseille, France., Gros FX; Hematology Department, CHU de Bordeaux, Bordeaux, France., le Bras F; Hematology Department, Hôpital Henri Mondor, Créteil, France., Bories P; Hematology Department, CHU de Toulouse, Toulouse, France., Choquet S; Hematology Department, Hôpital de la Pitié Salpêtrière and AP-HP Sorbonne Université, Paris, France., Rubio MT; Hematology Department, CNRS UMR 7365, CHRU de Nancy, Nancy, France., Iacoboni G; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., O'Reilly M; Department of Haematology, University College London Hospitals, London, UK., Casasnovas RO; Hematology Department, CHU de Dijon and INSERM 1231, Dijon, France., Bay JO; Hematology Department, CHU de Clermont Ferrand, Clermont-Ferrand, France., Mohty M; Hematology Department, Hôpital Saint Antoine, Inserm UMRs 938, Sorbonne University, Paris, France., Joris M; Hematology Department, CHU d'Amiens, Amiens, France., Abraham J; Hematology Department, CHU de Limoges, Limoges, France., Castilla Llorente C; Hematology Department, Gustave Roussy Cancer Campus, Villejuif, Paris, France., Loschi M; Hematology Department, CHU de Nice, Nice, France., Carras S; Hematology Department, Institute for Advanced Biosciences (INSERM U1209, CNRS UMR 5309), CHU de Grenoble and University Grenoble-Alpes, La Tronche, France., Chauchet A; Hematology Department, CHU de Besançon, Besançon, France., La Rochelle LD; Hematology Department, CHU de Tours, Tours, France., Hermine O; Hematology Department, Hôpital Necker, Paris, France., Guidez S; Hematology Department, CHU de Poitiers, Poitiers, France., Cony-Makhoul P; Medical and Scientific Affairs Department, LYSARC, Lyon, France., Fogarty P; Biostatistics Department, LYSARC, Lyon, France., Le Gouill S; Hematology Department, Institut Curie, Paris, France., Morschhauser F; Hematology Department, CHU de Lille, Lille, France.; ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille University, Lille, France., Gastinne T; Hematology Department, CHU de Nantes, Nantes, France., Cartron G; Hematology Department, CHU de Montpellier and UMR-CNRS, Montpellier, France., Subklewe M; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany., Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA., Sanderson R; Department of Haematology, King's College Hospital, London, UK., Barba P; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Houot R; Hematology Department, CHU de Rennes, Rennes, France., Bachy E; Hematology Department, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69410, Pierre Bénite, Lyon, France. emmanuel.bachy@chu-lyon.fr.; Lymphoma Immuno-Biology, CIRI, Inserm U1111, Lyon, France. emmanuel.bachy@chu-lyon.fr.

المصدر: Journal of hematology & oncology [J Hematol Oncol] 2024 Aug 06; Vol. 17 (1), pp. 61. Date of Electronic Publication: 2024 Aug 06.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy, Adoptive*/adverse effects , Immunotherapy, Adoptive*/methods , Antigens, CD19*/immunology , Lymphoma, Large B-Cell, Diffuse*/therapy , Lymphoma, Large B-Cell, Diffuse*/immunology , Cytokine Release Syndrome*/etiology, Humans ; Male ; Female ; Middle Aged ; Prognosis ; Aged ; Adult ; Neurotoxicity Syndromes/etiology ; Biological Products/therapeutic use ; Biological Products/adverse effects ; France ; Aged, 80 and over ; Receptors, Antigen, T-Cell

المؤلفون: Stathis A; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano. anastasios.stathis@eoc.ch., Pirosa MC; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona., Orsucci L; S.C. Ematologia, AOU Città della Salute e della Scienza di Torino, Turin., Feugier P; Department of Clinical Hematology, Nancy University Hospital, INSERM 1256, Nancy., Tani M; U.O. Ematologia, Dipartimento Oncologia e Ematologia, Ospedale Santa Maria delle Croci, Ravenna., Ghesquières H; Hematology Department, Hospices Civils de Lyon, CHU Lyon-Sud, Pierre-Bénite., Musuraca G; Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola., Rossi FG; Hematology-BMT Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano., Merli F; AUSL-IRCCS of Reggio Emilia, Reggio Emilia., Guièze R; Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont- Ferrand., Gyan E; Hématologie et thérapie cellulaire, CIC Inserm U1415, Centre Hospitalier Universitaire de Tours, Tours., Gini G; Hematology, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona., Marino D; Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova., Gressin R; Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble., Morschhauser F; Université de Lille, CHU Lille, Department of Hematology, Lille., Cavallo F; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU Città della Salute e della Scienza di Torino, Turin., Palombi F; Hematology and Stem Cell Transplant Unit, IRCCS. National Cancer Institute, Istituto Regina Elena, Rome Italy., Conconi A; Division of Hematology, Ospedale degli Infermi, Biella., Tessoulin B; Hématologie Clinique, CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes., Tilly H; Department of Hematology and U1245, Centre Henri Becquerel, Rouen., Zanni M; Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria., Cabras MG; Ospedale Oncologico, Ematologia e CTMO, Cagliari., Capochiani E; Hematology Unit, Azienda USL Toscana NordOvest, Center for Translational Medicine, Livorno., Califano C; Hematology Unit, P.O. A. Tortora, Pagani., Celli M; Hematology Unit, Ospedale degli Infermi, Rimini., Pulsoni A; Department of Translational and Precision Medicine, Sapienza University, Rome., Angrilli F; Unità Operativa Semplice Dipartimentale Centro Diagnosi e Terapia Linfomi, Presidio Ospedaliero, Pescara., Occhini U; Unità Operativa di Ematologia, Ospedale San Donato, AUSL Toscana Sud-Est, Arezzo., Casasnovas RO; Department of Hematology, University Hospital F Mitterrand and INSERM 1231, Dijon., Cartron G; Hématologie Clinique, CHU Montpellier, UMR 5535 Montpellier., Devizzi L; Hematology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan., Haioun C; Lymphoid Malignancies Unit, Hôpital Henri Mondor, AP-HP, Créteil., Liberati AM; SC Oncoematologia, Azienda Ospedaliera Santa Maria, Università degli studi di Perugia, Terni., Houot R; Department of Clinical Hematology, University Hospital of Rennes, Rennes., Merli M; Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi ASST Sette Laghi, University of Insubria, Varese., Pietrantuono G; Hematology Unit, Centro di Riferimento Oncologico della Basilicata IRCCS Rionero in Vulture., Re F; Hematology and BMT Center, Azienda Ospedaliera Universitaria, Parma., Spina M; Division of Medical Oncology, Centro di Riferimento Oncologico IRCCS, Aviano., Landi F; Oncology Institute of Southern Switzerland, EOC, Bellinzona., Cavalli F; Institute of Oncology Research, Bellinzona., Bertoni F; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland; Institute of Oncology Research, Bellinzona., Rossi D; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland; Institute of Oncology Research, Bellinzona., Ielmini N; Institute of Oncology Research, Bellinzona., Borgo E; FIL, Fondazione Italiana Linfomi ONLUS, Alessandria., Luminari S; AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy; CHIMOMO Department, University of Modena and Reggio Emilia, Reggio Emilia., Zucca E; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Medical Oncology, University Hospital and University of Bern., Thieblemont C; APHP - Service d'Hématologie-Oncologie, Hôpital Saint Louis, Université de Paris - Diderot, Paris.

المصدر: Haematologica [Haematologica] 2024 Aug 01; Vol. 109 (8), pp. 2564-2573. Date of Electronic Publication: 2024 Aug 01.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, B-Cell, Marginal Zone*/drug therapy , Lymphoma, B-Cell, Marginal Zone*/mortality , Rituximab*/administration & dosage , Rituximab*/therapeutic use , Chlorambucil*/administration & dosage , Chlorambucil*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Middle Aged ; Female ; Male ; Aged ; Adult ; Aged, 80 and over ; Maintenance Chemotherapy ; Injections, Subcutaneous ; Treatment Outcome ; Remission Induction

المؤلفون: Dupuis J; Service d'Hématologie Lymphoïde, AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Créteil, France. Electronic address: jehan.dupuis@aphp.fr., Bachy E; Service d'Hématologie Clinique, CHU Lyon Sud-Hospices Civils de Lyon, Pierre Bénite, France; Inserm U1111, International Center for Infectiology Research (CIRI), Lyon, France., Morschhauser F; Service des Maladies du Sang, ULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, CHU Lille, University of Lille, Lille, France., Cartron G; Département d'Hématologie Clinique, CHU de Montpellier-UMR-CNRS 5535, Montpellier, France., Fukuhara N; Department of Hematology, Tohoku University Hospital, Sendai, Japan., Daguindau N; Service Hématologie Clinique, Centre Hospitalier Annecy Genevois, Pringy, France., Casasnovas RO; Service d'Hématologie Clinique, CHU de Dijon, Inserm U1231, Dijon, France., Snauwaert S; Department of Hematology, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium., Gressin R; Service Hématologie Clinique, CHU de Grenoble-Hôpital Albert Michallon, Grenoble, France., Fox CP; School of Medicine, University of Nottingham, Nottingham, UK., d'Amore FA; Department of Hematology, Aarhus University Hospital, Aarhus Nord, Denmark., Staber PB; Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria., Tournilhac O; Service d'Hématologie Clinique et de Thérapie Cellulaire Adulte, CHU de Clermont-Ferrand-Hôpital Estaing, Clermont-Ferrand, France., Bouabdallah K; Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux-Hôpital Haut Lévêque-Centre François Magendie, Pessac, France., Thieblemont C; Université Paris Cité, Paris, France; Service d'hémato-oncologie, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, France., André M; Service Hématologie, CHU UCL Namur-Site Godinne, Yvoir, Belgium., Rai S; Department of Hematology & Rheumatology, Kindai University Hospital, Osakasayama, Japan., Ennishi D; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan., Gkasiamis A; Bristol Myers Squibb, Neuchâtel, Switzerland., Nishio M; Bristol Myers Squibb, Tokyo, Japan., Fornecker LM; Institut de Cancérologie Strasbourg Europe (ICANS) Strasbourg, France; University of Strasbourg, Strasbourg, France., Delfau-Larue MH; Laboratoire d'immunologie, AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Créteil, France; IMRB, INSERM, Université Paris Est Créteil, Créteil, France., Sako N; IMRB, INSERM, Université Paris Est Créteil, Créteil, France., Mule S; Département d'imagerie médicale, AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Créteil, France., de Leval L; Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Suisse., Gaulard P; Département de pathologie, AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Créteil, France; IMRB, INSERM, Université Paris Est Créteil, Créteil, France., Tsukasaki K; Department of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan., Lemonnier F; Service d'Hématologie Lymphoïde, AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Créteil, France; IMRB, INSERM, Université Paris Est Créteil, Créteil, France.

المصدر: The Lancet. Haematology [Lancet Haematol] 2024 Jun; Vol. 11 (6), pp. e406-e414.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Azacitidine*/therapeutic use , Azacitidine*/adverse effects , Azacitidine*/administration & dosage, Humans ; Male ; Female ; Aged ; Middle Aged ; Administration, Oral ; Bendamustine Hydrochloride/therapeutic use ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Gemcitabine ; Lymphoma, Follicular/drug therapy ; Lymphoma, Follicular/mortality ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Depsipeptides/therapeutic use ; Depsipeptides/adverse effects ; Depsipeptides/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antimetabolites, Antineoplastic/therapeutic use ; Antimetabolites, Antineoplastic/adverse effects ; Antimetabolites, Antineoplastic/administration & dosage ; Aged, 80 and over

المؤلفون: Rossi C; Department of Hematology, CHU Dijon Bourgogne.; INSERM 1231 Team Epi2THM ((Epi)genetics, Epidemiology and Targeted Therapy in Hematological Malignancies), Dijon, France.; Stanford University School of Medicine, Ash Alizadeh Lab, Stanford, California, USA., Casasnovas RO; Department of Hematology, CHU Dijon Bourgogne.; INSERM 1231 Team Epi2THM ((Epi)genetics, Epidemiology and Targeted Therapy in Hematological Malignancies), Dijon, France.

المصدر: Current opinion in oncology [Curr Opin Oncol] 2024 Sep 01; Vol. 36 (5), pp. 339-345. Date of Electronic Publication: 2024 Jun 25.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9007265 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-703X (Electronic) Linking ISSN: 10408746 NLM ISO Abbreviation: Curr Opin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Hodgkin Disease*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Positron-Emission Tomography ; Randomized Controlled Trials as Topic ; Immune Checkpoint Inhibitors/therapeutic use ; Molecular Targeted Therapy

المؤلفون: Dann EJ; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel.; Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa 3109601, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel., Casasnovas RO; Department of Hematology, CHU Dijon Bourgogne, 21000 Dijon, France.; INSERM 1231 Team Epi2THM ((Epi)genetics, Epidemiology and Targeted Therapy in Hematological Malignancies), 21000 Dijon, France.

المصدر: Cancers [Cancers (Basel)] 2024 May 29; Vol. 16 (11). Date of Electronic Publication: 2024 May 29.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Camus V; Department of Hematology, Centre Henri Becquerel, Rouen, France., Thieblemont C; Hematology Department, Hospital Saint-Louis, Paris, France., Gaulard P; Department of Pathology and InsermU955, University Hospital Henri Mondor, Créteil, France., Cheminant M; Service d'Hematologie adultes, Hopital Universitaire Necker Enfants Malades, AP-HP, Paris, France., Casasnovas RO; Department of Hematology, CHU Dijon-Bourgogne and INSERM 1231, Dijon, France., Ysebaert L; IUCT Oncopole, Toulouse, France., Damaj GL; CHU de Caen Normandie, Normandie, France., Guidez S; Service d'Hématologie, CHU de Poitiers, Poitiers, France., Pica GM; Department of Hematology, Centre Hospitalier Métropole Savoie Chambéry, Chambéry, France., Kim WS; Samsung Medical Center, Seoul, South Korea., Lim ST; National Cancer Centre Singapore, Singapore., Andre M; Department of Hematology, CHU UCL Namur, Yvoir, Belgium., Gutiérrez N; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain., Penarrubia MJ; Hospital Clinico Universitario de Valladolid, Valladolid, Spain., Staber PB; Division of Hematology, Department of Medicine I, Medical University Vienna, Vienna, Austria., Trotman J; Concord Repatriation General Hospital, University of Sydney, Concord, Australia., Hüttmann A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Stefoni V; Policlinico Sant'Orsola-Malpighi, Bologna, Italy., Tucci A; Hematology Division, Spedali Civili di Brescia, Brescia, Italy., Fogarty P; Biostatistics Department, LYSARC, Hôpital Lyon-Sud, Pierre-Bénite, France., Farhat H; Department of Oncology-Hematology, Centre Hospitalier de Versailles, Le Chesnay, France., Abraham J; Department of Hematology, Centre Hospitalo-universitaire (CHU) Dupuytren, Limoges, France., Abarah W; Department of Hematology, Grand Hôpital de l'Est Francilien, Meaux, France., Belmecheri F; Department of Hematology, Institut Paoli-Calmettes, Marseille, France., Ribrag V; Department of Hematology, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France., Delfau-Larue MH; Department of Immunobiology and InsermU955, University Hospital Henri Mondor, Créteil, France., Cottereau AS; Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Cité University, Paris, France., Itti E; Department of Nuclear Medicine, CHU Henri Mondor, Créteil, France., Li J; Bristol Myers Squibb Company, Princeton, NJ., Delarue R; Service d'Hematologie adultes, Hopital Universitaire Necker Enfants Malades, AP-HP, Paris, France., de Leval L; Institute of Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland., Morschhauser F; Univ. Lille, CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France., Bachy E; Hospices Civils De Lyon, Lyon, France.; Claude Bernard Lyon 1 University, Lyon, France.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 10; Vol. 42 (14), pp. 1612-1618. Date of Electronic Publication: 2024 Feb 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, T-Cell, Peripheral*/drug therapy , Lymphoma, T-Cell, Peripheral*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Cyclophosphamide*/administration & dosage , Cyclophosphamide*/therapeutic use , Doxorubicin*/administration & dosage , Doxorubicin*/therapeutic use , Vincristine*/administration & dosage , Vincristine*/therapeutic use , Prednisone*/administration & dosage , Prednisone*/therapeutic use , Depsipeptides*/administration & dosage , Depsipeptides*/therapeutic use, Humans ; Middle Aged ; Male ; Female ; Aged ; Adult ; Progression-Free Survival

SCR Protocol: CHOP protocol

المؤلفون: Carlier T; Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France.; Nuclear Medicine Department, University Hospital, Nantes, France., Frécon G; Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France.; Nuclear Medicine Department, University Hospital, Nantes, France., Mateus D; Laboratoire des Sciences Numériques de Nantes, Ecole Centrale de Nantes, CNRS UMR 6004, Nantes, France., Rizkallah M; Laboratoire des Sciences Numériques de Nantes, Ecole Centrale de Nantes, CNRS UMR 6004, Nantes, France., Kraeber-Bodéré F; Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France.; Nuclear Medicine Department, University Hospital, Nantes, France., Kanoun S; Nuclear Medicine, Georges-François Leclerc Center, Dijon, France., Blanc-Durand P; Nuclear Medicine, CHU Henri Mondor, Paris-Est University, Créteil, France., Itti E; Nuclear Medicine, CHU Henri Mondor, Paris-Est University, Créteil, France., Le Gouill S; Haematology Department, University Hospital, Nantes, France; and., Casasnovas RO; Hematology, CHU Dijon Bourgogne, Dijon, France., Bodet-Milin C; Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France.; Nuclear Medicine Department, University Hospital, Nantes, France., Bailly C; Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France; clement.bailly@chu-nantes.fr.; Nuclear Medicine Department, University Hospital, Nantes, France.

المصدر: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Jan 02; Vol. 65 (1), pp. 156-162. Date of Electronic Publication: 2024 Jan 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE

مواضيع طبية MeSH: Fluorodeoxyglucose F18* , Lymphoma, Large B-Cell, Diffuse*/diagnostic imaging , Lymphoma, Large B-Cell, Diffuse*/therapy, Humans ; Prognosis ; Positron Emission Tomography Computed Tomography/methods ; Radiomics ; Neoplasm Recurrence, Local ; Retrospective Studies